Caribou Biosciences (CRBU) vs Greenland Mines (GRML)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Caribou Biosciences (CRBU) has outperformed Greenland Mines (GRML) over the past year, losing 74.6% versus a loss of 80.4%. Greenland Mines is the larger company by market cap ($77.8 million vs $66.2 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRBU | GRML |
|---|---|---|
| Share price | $0.6174 | $5.83 |
| Market cap | $66.19M | $77.81M |
| 1-day change | -45.60% | -8.62% |
| YTD return | -61.17% | -59.65% |
| 1-year return | -74.59% | -80.37% |
| 5-year return | -97.04% | — |
| EPS (TTM) | $-1.08 | $-9.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.54 | $37.00 |
| 52-week low | $0.546 | $2.82 |
| Distance from 52-week high | -82.53% | -84.24% |
| Average volume | 1.31M | 7.99M |
| Shares outstanding | 107.21M | 13.35M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
CRBU vs GRML FAQ
Which is bigger, Caribou Biosciences or Greenland Mines?
Greenland Mines (GRML) is larger, with a market capitalization of $77.81M compared with $66.19M for Caribou Biosciences (CRBU).
Which stock has performed better over the past year, CRBU or GRML?
CRBU returned -74.59% over the past 12 months, compared with -80.37% for GRML (price return, excluding dividends). Past performance does not predict future results.
Are Caribou Biosciences and Greenland Mines in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.